Option chain shows key data for Curis's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Curis.

Curis (NASDAQ:CRIS) Stock, Option Chain

Curis

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

News

Penny Stocks

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

CRIS

RVMD

As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Health Care Stocks That May Collapse In Q2

Price Target

Analyst Ratings

CYBR

LBTYA

NOTV

PCTY

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

CyberArk Software To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Friday

Small Cap

Intraday Update

Movers

ANVS

DWAC

ENSC

EVAX

EVER

GETR

GPAK

GYRE

HRTX

KURA

LCID

MMAT

NFLX

NYXH

PRPL

RDHL

RVSN

SAVE

SBEV

SIDU

SMMT

SPRC

SRAD

SWIN

VSME

Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $160 million of convertible senior notes.

BlackBerry shares tumbled 17.2% to $2.9387 on Wednesday.

Why BlackBerry Shares Are Trading Lower By Over 17%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Curis Inc

CRISPR Therapeutics AG

CRISM THERAPEUTICS CORP by CRISM THERAPEUTICS CORP

Crism Therapeutics Corp

HC Wainwright &amp; Co. analyst Edward White reiterates Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) with a Buy and maintains $20 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Curis, Maintains $20 Price Target

Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) reported quarterly losses of $(1.70) per share which beat the analyst consensus estimate of $(1.83) by 7.1 percent. This is a 20.19 percent increase over losses of $(2.13) per share from the same period last year.

Earnings

Curis Q3 2024 GAAP EPS $(1.70) Beats $(1.83) Estimate, Cash And Cash Equivalents Of $31.6M Is Expected To Provide Cash Runway Into Mid-2025

AFMD

AGAE

AIRI

AKYA

AMAT

AQMS

AREC

ASND

ASTS

AZUL

BENF

BILI

BIOR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BKTI

BKYI

BLUE

BNAI

BNZI

BRAG

BTAI

CASI

CELC

CINT

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNVS

CWCO

DARE

DBGI

DESP

DFLI

DLPN

DMRC

DNMR

DPRO

DTST

EAST

EFXT

ELUT

EWCZ

FLNT

FTLF

GAMB

GAME

GCTS

GDEV

GLOB

HYLN

IMCC

INKT

INTR

ITRM

IVVD

IZEA

LCTX

LIQT

LOCL

LUNR

MITQ

MOVE

MSGM

MUFG

NICE

NOMD

NTES

OCFT

OCUL

OKLO

ONEW

ORGN

PDSB

PHGE

POCI

POST

Earnings Scheduled For November 14, 2024

Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) is preparing to release its quarterly earnings on Thursday, 2024-11-14. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Curis to report an earnings per share (EPS) of $-1.84.
Anticipation surrounds Curis's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.36, leading to a 1.21% increase in the share price on the subsequent day.
Here's a look at Curis's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.67</td>
<td>-2.12</td>
<td>-2.11</td>
<td>-2.33</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-2.03</td>
<td>-2.05</td>
<td>-2.03</td>
<td>-2.13</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>1.0%</td>
<td>-2.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731517418_0.png" alt="eps graph" />
<h3>Performance of Curis Shares</h3>
Shares of Curis were trading at $4.12 as of November 12. Over the last 52-week period, shares are down 34.69%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/CRIS/earnings">To track all earnings releases for Curis visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Examining the Future: Curis's Earnings Outlook

Curis 13G Filing Shows Thomas A. Satterfield, Jr. Reported A 8.05% Stake In The Co As Of October 30, 2024

HC Wainwright &amp; Co. analyst Edward White maintains Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) with a Buy and lowers the price target from $26 to $20.

HC Wainwright & Co. Maintains Buy on Curis, Lowers Price Target to $20

The unregistered warrants to be issued in the concurrent private placement will have an exercise price of $4.92 per share of common stock, will be exercisable immediately and will expire five years following the issuance date. The combined purchase price for one share of common stock and the associated unregistered warrant is $5.045.

Biotech

Health Care

Financing

Offerings

General

Curis Has Announced A Registered Direct Offering Of 2.39M Shares Priced At-The-Market And A Concurrent Private Placement Of Unregistered Warrants To Purchase Up To An Aggregate Of 2.398M Shares

HC Wainwright &amp; Co. analyst Edward White reiterates Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) with a Buy and maintains $26 price target.

HC Wainwright & Co. Reiterates Buy on Curis, Maintains $26 Price Target

Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) reported quarterly losses of $(2.03) per share which missed the analyst consensus estimate of $(1.67) by 21.56 percent. This is a 17.81 percent increase over losses of $(2.47) per share from the same period last year. The company reported quarterly sales of $2.546 million which beat the analyst consensus estimate of $2.064 million by 23.37 percent. This is a 15.89 percent increase over sales of $2.197 million the same period last year.

Earnings Beats

Earnings Misses

Curis Q2 2024 GAAP EPS $(2.03) Misses $(1.67) Estimate, Sales $2.546M Beat $2.064M Estimate

<h3>Gainers</h3>
<ul>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock moved upwards by 34.0% to $0.82 during Monday's regular session. The company's market cap stands at $124.5 million. </li>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) shares increased by 32.51% to $1.71. The market value of their outstanding shares is at $252.1 million. </li>
<li>Champions Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSBR#NASDAQ">CSBR</a>) shares increased by 22.82% to $5.65. The company's market cap stands at $76.8 million. </li>
<li>Nanoviricides (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#AMEX">NNVC</a>) stock rose 22.02% to $3.26. The market value of their outstanding shares is at $38.4 million. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) stock moved upwards by 20.13% to $38.0. The market value of their outstanding shares is at $268.5 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock moved upwards by 18.63% to $1.3. The company's market cap stands at $8.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock fell 35.6% to $0.36 during Monday's regular session. The company's market cap stands at $6.8 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock fell 31.74% to $3.55. The company's market cap stands at $2.7 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock decreased by 27.83% to $3.65. The company's market cap stands at $1.1 million. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) stock fell 19.58% to $7.11. The company's market cap stands at $41.9 million. </li>
<li>Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) stock fell 15.0% to $9.3. The market value of their outstanding shares is at $261.0 million. </li>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares decreased by 14.62% to $15.52. The company's market cap stands at $2.2 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CNSP

CSBR

MCRB

NNVC

NVAX

RENB

RNAZ

SBFM

SKYE

SMLR

THAR

12 Health Care Stocks Moving In Monday's Intraday Session

Truist Securities analyst Robyn Karnauskas maintains Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) with a Buy and maintains $26 price target.

Truist Securities Maintains Buy on Curis, Maintains $26 Price Target

Cantor Fitzgerald analyst Li Watsek reiterates Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) with a Overweight.

Cantor Fitzgerald Reiterates Overweight on Curis

Data update expands AML dataset from 5 to 30 patients
LEXINGTON, Mass., May 14, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced updated data from the ongoing TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) AML to be presented at the ASCO and EHA conferences.
This update includes data for 25 new patients in the FLT3 mutation (FLT3m) and U2AF1/SF3B1 Splicing Factor mutation (SFm) cohorts who had received fewer than 3 lines of prior therapy and were treated with emavusertib as monotherapy at the Recommended Phase 2 Dose (RP2D) of 300 mg BID.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">
Prior
Data
</td>
<td colspan="2" rowspan="1">New Data&#x2A;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Total</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">FLT3m AML</td>
<td colspan="2" rowspan="1">3</td>
<td colspan="1" rowspan="1">9</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">12</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">SFm AML</td>
<td colspan="2" rowspan="1">3</td>
<td colspan="1" rowspan="1">17</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">20</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">adjustment for patients with dual mutation&#x2A;&#x2A;</td>
<td colspan="2" rowspan="1">(1)</td>
<td colspan="1" rowspan="1">(1)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">(2)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">5</td>
<td colspan="1" rowspan="1">25</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">30</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
</tbody>
</table>
</figure>
&#x2A;&nbsp; data cut-off as of February 26, 2024 &#x2A;&#x2A;&nbsp; 2 patients had both FLT3m and SFm (dual mutation) &nbsp; &nbsp; 1 patient in the initial group of 5 patients; 1 patient in the new group of 25 additional patients

Curis To Present Updated Data From TakeAim Leukemia Study  At The ASCO And EHA Conferences

Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) reported quarterly losses of $(2.05) per share which beat the analyst consensus estimate of $(2.12) by 3.3 percent. This is a 14.58 percent increase over losses of $(2.40) per share from the same period last year. The company reported quarterly sales of $2.09 million which missed the analyst consensus estimate of $2.40 million by 13.08 percent. This is a 9.19 percent decrease over sales of $2.30 million the same period last year.

Curis Q1 EPS $(2.05) Beats $(2.12) Estimate, Sales $2.09M Miss $2.40M Estimate

As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#39;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#39;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi"> RSI is above 70</a>, according to <a href="https://pro.benzinga.com/"> Benzinga Pro</a>.
Here&rsquo;s the latest list of major overbought players in this sector.
<h3>OncoCyte Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocx#NASDAQ">OCX</a>)</h3>
<ul>
<li>On April 11, Oncocyte announced a $15.8 million private placement of securities priced at-the-market under Nasdaq rules. The company&rsquo;s stock gained around 4% over the past five days and has a <a href="https://www.benzinga.com/quote/OCX">52-week high of $6.80 </a>.</li>
<li>RSI Value: 73.87</li>
<li>OCX Price Action: Shares of OncoCyte rose 1.2% to close at $2.9650 on Thursday.</li>
</ul>
<h3>Curis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cris#NASDAQ">CRIS</a>)</h3>
<ul>
<li>On April 5, Curis reported inducement grants under NASDAQ Listing Rule 5635(c)(4). The company&rsquo;s stock gained around 59% over the past month and <a href="https://www.benzinga.com/quote/CRIS"> has a 52-week high </a> of $17.49.</li>
<li>RSI Value: 75.26</li>
<li>CRIS Price Action: Shares of Curis gained 4.1% to close at $15.90 on Thursday.</li>
</ul>
<h3>Revolution Medicines, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvmd#NASDAQ">RVMD</a>)</h3>
<ul>
<li>On April 9, the company announced the publication of a research paper on RMC-6236 in Cancer Discovery. The company&rsquo;s stock gained around 25% over the past five days and has a <a href="https://www.benzinga.com/quote/RVMD"> 52-week high </a> of $38.73.</li>
<li>RSI Value: 72.27</li>
<li>RVMD Price Action: Shares of Revolution Medicines gained 2.5% to close at $37.41 on Thursday.</li>
</ul>
&nbsp;
Read More: <a href="https://www.benzinga.com/news/earnings/24/04/38215617/fear-greed-index-moves-to-greed-zone-following-ppi-data-nasdaq-record-sharp-gains"> Fear &amp; Greed Index Moves To &#39;Greed&#39; Zone Following PPI Data; Nasdaq record Sharp Gains </a>

<h3>Gainers</h3>
<ul>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) shares moved upwards by 64.3% to $2.76 during Thursday's regular session. The market value of their outstanding shares is at $80.9 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares increased by 61.38% to $2.1. The market value of their outstanding shares is at $5.0 million. </li>
<li>Eiger BioPharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EIGR#NASDAQ">EIGR</a>) shares moved upwards by 38.18% to $2.28. The company's market cap stands at $3.3 million. </li>
<li>Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) stock rose 32.55% to $18.12. The company's market cap stands at $1.1 billion. </li>
<li>Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) shares increased by 29.55% to $3.77. The company's market cap stands at $146.7 million. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) shares moved upwards by 24.62% to $16.7. The market value of their outstanding shares is at $98.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>eFFECTOR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFTR#NASDAQ">EFTR</a>) stock declined by 80.2% to $3.25 during Thursday's regular session. The company's market cap stands at $11.9 million. </li>
<li>Achilles Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHL#NASDAQ">ACHL</a>) stock decreased by 24.17% to $0.91. The market value of their outstanding shares is at $37.1 million. As per the press release, Q4 earnings came out today. </li>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) shares fell 16.81% to $7.87. The company's market cap stands at $202.9 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock declined by 14.55% to $2.35. The company's market cap stands at $8.5 million. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) shares declined by 13.48% to $0.14. The market value of their outstanding shares is at $5.5 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) stock declined by 12.85% to $2.51. The market value of their outstanding shares is at $48.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACHL

BRNS

CADL

CTCX

EFTR

EIGR

Kintara Therapeutics, Inc. - Common Stock

KTRA

MGNX

TCBP

12 Health Care Stocks Moving In Thursday's Intraday Session

H.C. Wainwright analyst Edward White reiterated a Buy rating on Curis (CRIS – Research Report) today and set a price target of $20.00. Edward White...

Curis Inc. Gains 'Buy' Rating Amid Financial Stability and Promising Clinical Developments

Curis up 4% on emavusertib data in myelodysplastic syndrome

Curis Q3 2024 Earnings Preview

Here's the major earnings before the open tomorrow

Curis GAAP EPS of -$1.70 beats by $0.17, revenue of $2.93M beats by $0.56M

Curis, Inc. (CRIS) Q3 2024 Earnings Call Transcript

Curis Inc. Receives Buy Rating: Strong Financials and Promising Clinical Trial Progress Drive Growth Potential

Orphan designation was granted by the FDA to Curis (CRIS) Inc's emavusertib for the treatment of primary central nervous system lymphoma, according...

Curis granted FDA orphan designation for emavusertib

Comments

Curis

Curis (CRIS) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga